Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Acrivon Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Acrivon Therapeutics, Inc.

ACRV

Acrivon Therapeutics, Inc.

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 proteomics platform. The company designs targeted cancer therapies and companion OncoSignature diagnostics to identify patients most likely to respond, focusing on tumors beyond genomics-based selection. Its pipeline includes selective inhibitors like ACR-368 and ACR-2316, aimed at treating solid tumors with high unmet needs through biomarker-driven patient stratification and rational drug combinations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Acrivon Therapeutics, Inc.

1
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports $19M Net Loss in Q1 2026, Cash Position Decreases

Via official filing (AI summary) | 26 days ago | 0 comments

2
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports $77.9 Million Net Loss for 2025, Advances Drug Pipeline

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports $18.2 Million Net Loss in Q3 2025, Advances Clinical Pipeline

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports $21M Net Loss in Q2 2025, Focuses on Oncology Pipeline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports $19.7 Million Net Loss in Q1 2025, Increases R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports $80.6 Million Net Loss for 2024, Highlights Clinical Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Acrivon Therapeutics, Inc. Acrivon Therapeutics Reports Strong Asset Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments